Form 4: FibroBiologics CEO Granted Stock Options
SEC Form 4
FibroBiologics CEO Pete O'Heeron was granted options to purchase 406,339 shares of common stock on December 27, 2024.
Summary
- On December 27, 2024, Pete O'Heeron, CEO of FibroBiologics, Inc., was granted an option to purchase 406,339 shares of the company's common stock.
- The exercise price of the stock option is $2.36.
- The options vest over a period of four years, with one-fourth vesting on the one-year anniversary of the grant date and the remaining balance vesting in 36 equal monthly installments, contingent upon continuous service.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard executive compensation practice, with no immediately positive or negative implications.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Stakeholder Impact
- Shareholders may view the option grant as a positive incentive for the CEO.
- Employees may see the grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 12/27/2024 | Date of stock option grant to Pete O'Heeron. |
| 12/26/2034 | Expiration date of the stock options. |
| 12/30/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.